Manufactures and exports dental products for clinics, dental laboratories and OEMs, with a product range spanning endodontic files (Rotoflex), oral-care items (Oradox), 3D-printing resins, Omni-branded 3D printers, and a newly commercialised disinfectant line for dental and medical settings. Revenue of INR 71.81 crore in FY26 grew 13.9% year-on-year, with exports contributing the larger share and rising 17.58% across 90-92 countries; the US subsidiary Axiodent grew 37.58% via private-label and direct sales. Domestic sales rose 9%, weighed in H1 by GST changes and Jammu floods before recovering in H2. Digital dentistry (3D printers and resins) is the priority growth area, with 3D-printer unit sales up 162% and resin volumes up 40.5%; a fully indigenous 3D printer is targeted by 2028. The company operates through three subsidiaries (Denvisio Biomed in India, Axiodent in the US, and the newly formed Prevest Denpro Gulf in the UAE for Dubai-based import/export and trading) and supplies 3-4 large multinational OEMs. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Dental consumables and endodontic products, Digital dentistry — 3D printers and resins, Disinfectants and hygiene products, Oral-care consumer products, OEM and private-label supply. Asset-light specialty dental manufacturer with three overseas subsidiaries, high gross margins and zero debt.
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 56 | 63 | 72 |
| EBITDA (ex other income) | — | — | — |
| margin % | — | — | — |
| Owners' profit | — | — | — |
| EPS, as reported (₹) | 13.45 | 15.13 | 17.07 |
| ROE % · ROCE % | — · 24.0 | — · 22.8 | — · 21.9 |
| Debt / equity (x) | — | — | — |
| Cash from operations | 12 | 15 | 15 |
| Capex | — | 0 | (2) |
| ₹ crore | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 27 | 30 | 30 | 33 | 16 | 34 | 18 | 37 |
| Profit before tax | 10 | 11 | 11 | 13 | 6 | 13 | 6 | 14 |
| Net profit | — | — | — | — | — | — | — | — |
| EPS (₹) | 6.52 | 7.01 | 7.07 | 8.06 | 3.67 | 8.29 | 3.93 | 8.78 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| POLY MEDICURE LIMITED | 17,626 | 55.9 | 5.60 | 32.3 | 10.2 | 12.6 | 19.0 | 30.2 |
| FISCHER MEDICAL VENTURE L | 2,353 | 15.0 | 6.11 | 43.6 | 8.1 | 11.3 | — | 15.5 |
| TARSONS PRODUCTS LIMITED | 1,657 | 149.0 | 2.61 | 14.3 | 2.3 | 2.4 | — | 29.0 |
| LAXMI DENTAL LIMITED | 1,121 | 36.0 | 4.59 | 24.1 | 11.8 | 11.0 | — | 22.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 21 Aug 2026 · 27th AGM notice and e-voting info published in newspapers | compliance | minimal | — | — |
| 20 Aug 2026 · AGM notice sent to shareholders without registered email | compliance | minimal | — | — |
| 20 Aug 2026 · Prevest DenPro files FY2026 annual report; AGM set for September 17 | board shareholder meetings | medium | — | — |
| 20 Aug 2026 · Notice of 27th AGM on Sep 17, 2026 - Final Dividend of Rs 1 per share | board shareholder meetings | low | — | — |
| 19 Aug 2026 · 27th AGM notice published; final dividend of Re 1 per share recommended | compliance | minimal | — | — |
| 11 Aug 2026 · Q1 FY27: revenue up 21% YoY, PAT up 28% YoY; 10% dividend declared | compliance | low | — | — |
| 11 Aug 2026 · Record date fixed for final dividend FY 2025-26 | corporate actions | medium | — | — |
| 11 Aug 2026 · Prevest Denpro Q1 FY27 PAT up 28% YoY at Rs 5.64 cr; 10% dividend declared | results | high | — | — |
| 11 Aug 2026 · Q1 FY27 Results: Revenue up 21%, PAT up 28% YoY; Final Dividend Recommended | results | high | — | — |
| 5 Aug 2026 · Board meeting set for Aug 11 to consider Q1 results and final dividend | results | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| FABTECH TECHNOLOGIES LTD |
| 650 |
| 10.6 |
| 1.55 |
| 10.6 |
| 9.1 |
| 10.7 |
| — |
| 9.9 |
| Hemant Surgical Industries Lim | 613 | 23.4 | — | — | — | 16.7 | — | — |
| Prevest Denpro Limited ◆ | 489 | 16.5 | — | — | — | 21.9 | — | — |
| NURECA LIMITED | 318 | 65.2 | 1.76 | 38.3 | 1.2 | 2.7 | (7.2) | 13.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 16.5 | 20.0 | 8 of 17 | 56% |
| ROCE | 21.9 | 11.3 | 3 of 17 | 88% |
| Revenue growth | 12.0 | 13.9 | 9 of 13 | 33% |
| Market cap | 489 | 175 | 7 of 17 | 63% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
